沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

休市中 04-30 16:08:13

6.190

-0.170

-2.67%

最高6.350	最低6.150	成交量129.60万
今开6.350	昨收6.360	日振幅3.14%
总市值41.60亿	流通市值41.60亿	总股本6.72亿
成交额802.55万	换手率0.19%	流通股本6.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":6.19,"timestamp":1777536493009,"preClose":6.36,"halted":0,"volume":1296000,"delay":0,"changeRate":-0.02672955974842766,"floatShares":672000000,"shares":672000000,"eps":-0.35042471898113325,"marketStatus":"休市中","change":-0.17,"latestTime":"04-30 16:08:13","open":6.35,"high":6.35,"low":6.15,"amount":8025490,"amplitude":0.031447,"askPrice":6.19,"askSize":1000,"bidPrice":6.17,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-0.35042471898113325,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":7,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":6.36,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":1.122466655050604,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996","defaultTab":"news","newsList":[{"id":"2631251557","title":"贝康医疗-B(02170)：PGT-M试剂盒获国家药监局颁发三类医疗器械证","url":"https://stock-news.laohu8.com/highlight/detail?id=2631251557","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631251557?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:40","pubTimestamp":1777462801,"startTime":"0","endTime":"0","summary":"本次获批的PGT-M试剂盒是国内首个针对地中海贫血家系遗传阻断的PGT-M产品，填补了我国单基因病胚胎植入前遗传学检测领域的国产空白。随着PGT-M试剂盒获批上市，集团的产品线进一步丰富，将有效带动遗传实验室业务收入增长，有望成为公司未来业绩增长的重要驱动力，并进一步巩固集团在中国三代试管婴儿基因检测试剂盒市场的领导地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1100","02170","09997","BK1574","BK1597","09996","BK1583","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631552565","title":"海 利 得：浙江海利得医疗器械有限公司初期将聚焦医用纤维，切入生命科学领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2631552565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631552565?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:38","pubTimestamp":1777433910,"startTime":"0","endTime":"0","summary":"证券之星消息，海 利 得(002206)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问贵司新成立的医疗科技公司将销售什么材料的产品？是TPU吗？请问预计何时将产生收入？谢谢海 利 得回复：您好，感谢您的关注。浙江海利得医疗器械有限公司初期将聚焦医用纤维，切入生命科学领域。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900037846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","BK1222","BK0201","09996","002206","09997","BK0208","BK1100","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629483145","title":"华东医药最新公告：全资子公司伊妍仕M型获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2629483145","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629483145?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:31","pubTimestamp":1776947476,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司欣可丽美学(杭州)供应链管理有限公司收到国家药监局签发的《医疗器械注册证》，其代理申报的三类医疗器械注射用聚己内酯微球面部填充剂Ellansé伊妍仕M型(商品名：伊妍仕恒耀TM)注册申请获得上市批准。该产品适用于改善成人轻中度颞部凹陷。此次获批将进一步夯实并扩容公司高端再生医美产品管线，完善高端注射医美产品矩阵，对公司医美业务有积极影响，但不会对公司当前财务状况和经营成果产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300058247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK1574","BK1222","09996","BK0209","BK1583","LU2328871848.SGD","BK0187","BK0188","BK1100","LU1969619763.USD","BK0175","BK0183","BK0132","159883","09997","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186689803","title":"沛嘉医疗拟回购最多一成股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1186689803","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186689803?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:47","pubTimestamp":1776934056,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B于香港联合交易所主要上市。根据公司最新公告，董事会已提呈一项股份购回计划，授权比例最高可达已发行股本总面值的10%，相当于约672,060,659股中最多67,206,065股。相关授权有待股东于2026年5月29日举行的股东大会批准。公司提醒，股东大会的决议结果将决定回购授权能否生效。董事会建议股东关注大会日期并遵从相关手续安排。所有购回股份可依法注销或存入库存股，并按相关规则办理后续事宜。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"沛嘉医疗拟回购最多一成股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122106659","title":"沛嘉医疗-B2025年收入增长15.8%至7.13亿元 结构性心脏病与神经介入双线并进","url":"https://stock-news.laohu8.com/highlight/detail?id=1122106659","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122106659?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:46","pubTimestamp":1776933979,"startTime":"0","endTime":"0","summary":"在截至2025年12月31日止年度，沛嘉医疗-B实现收入人民币7.13亿元，同比增长15.8%。毛利约4.86亿元，同比增长12.1%。年内亏损为2.08亿元，较2024年的2.28亿元收窄8.9%，归属于公司拥有人的亏损为2.03亿元，每股基本及摊薄亏损由上年的0.34元降至0.31元。其中，TAVR相关产品收入约2.90亿元，同比增长1.6%；神经介入业务收入约4.23亿元，同比增长18.9%。公司计划在现有TAVR与神经介入业务上进一步深化技术创新及商业化落地，持续挖掘介入治疗领域的增长潜力。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"沛嘉医疗-B2025年收入增长15.8%至7.13亿元 结构性心脏病与神经介入双线并进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886163","title":"红日药业：当前战略聚焦于成品药、中药配方颗粒、原辅料、医疗器械等核心主业的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629886163?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:33","pubTimestamp":1776933187,"startTime":"0","endTime":"0","summary":"证券之星消息，红日药业(300026)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：控股股东成都兴城投资集团有限公司收购红日药业已经有7年了，为什么价格越来越低，作为控股股东旗下的医美资产，养老康养资产什么时候注入红日药业啊？红日药业回复：您好，红日药业当前战略聚焦于成品药、中药配方颗粒、原辅料、医疗器械等核心主业的发展。对于医美及康养资产注入尚无明确计划，请以公司公告为准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300045036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1222","09996","BK1583","300026","159883","BK0239","BK0188","BK1100","09997","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629090985","title":"迈瑞医疗：公司中长期的战略方向是希望用未来十年时间进入全球前10名医疗器械公司的榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2629090985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629090985?lang=zh_cn&edition=full","pubTime":"2026-04-22 15:21","pubTimestamp":1776842469,"startTime":"0","endTime":"0","summary":"证券之星消息，迈瑞医疗04月22日在投资者关系平台上答复投资者关心的问题。公司中长期的战略方向是希望用未来十年时间进入全球前10名医疗器械公司的榜单。未来五年，迈瑞不可避免将与成熟的全球头部医疗器械企业在国际市场上正面竞争，我们要逐渐向他们看齐，这个底气来自于迈瑞深耕行业几十年所掌握的核心技术，甚至在很多方面，我们已经达到行业领先水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200030381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1146622755.USD","IE00B29SXG58.USD","LU2488822045.USD","LU2424517915.HKD","IE00B031J352.USD","LU1688375341.USD","BK0251","IE00B031HY20.USD","LU0823426480.USD","LU2348773727.SGD","LU1997245094.SGD","LU1023057109.AUD","LU0594300419.USD","LU0327786744.USD","159883","LU0594300179.USD","LU1064131003.USD","IE0008368742.USD","SGXZ49509284.SGD","LU1064130708.USD","BK1222","LU0359201612.USD","LU1655091616.SGD","LU2153592121.USD","LU0605514214.HKD","SGXZ81163826.USD","300760","09996","BK1574","LU1979443071.USD","LU1820825898.SGD","LU2153591404.USD","LU1580142542.USD","LU1781817850.SGD","LU1794554557.SGD","LU0572944931.SGD","BK1100","LU0405327494.USD","LU0823426308.USD","LU2148510915.USD","LU1734074674.USD","LU0084288322.USD","LU0650527681.SGD","LU0405327148.USD","LU2348774022.SGD","LU2213484517.USD","LU1934453819.USD","LU0359202008.SGD","09997","IE0005HP3H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629087757","title":"【券商聚焦】中信建投：医疗器械板块拐点来临 26年业绩改善个股存在业绩估值修复机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2629087757","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629087757?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:19","pubTimestamp":1776734371,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究认为，医疗器械板块拐点已经来临，26年业绩改善个股存在业绩估值修复机会。建议持续关注市场空间大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等主题方向的投资机会。潜在催化较多的方向有望出现涨幅数倍的个股，未来AI医疗、脑机接口等也有望成为投资人重点关注的新科技方向。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979495","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1222","BK1571","01066","BK1247","00241","00853","BK1574","BK1142","BK1189","06826","601066","BK1617","BK0276","02235","BK1615","BK1585","LU0173614495.USD","159883","LU0287142896.SGD","BK1593","BK1587","BK1584","BK1502","09997","BK1589","BK1600","BK1583","BK1515","BK1501","BK1100","02252","BK1610","BK1591","01302","02190","BK1161","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721959","title":"中生北控生物科技(08247)附属中生济南自主研发的ZS-2000全自动生化分析仪获发医疗器械注册证上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721959","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628721959?lang=zh_cn&edition=full","pubTime":"2026-04-20 22:36","pubTimestamp":1776695791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中生北控生物科技 发布公告，公司的附属公司中生医疗器械科技(济南)有限公司自主研发的ZS-2000全自动生化分析仪，近日已获得中国山东省药品监督管理局颁发的中国医疗器械注册证。此外，董事会认为，ZS-2000全自动生化分析仪的成功上市，并合作推出ZS-8600生化免疫一体机，有助于集团进一步拓展国内医疗检测市场，推动相关配套试剂产品销售，符合集团长远发展战略。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["08247","09997","BK1161","BK1574","BK1583","BK1100","159883","09996","IPOS","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628749778","title":"科美诊断（688468）披露公司获得医疗器械注册证，4月20日股价上涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628749778","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628749778?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:57","pubTimestamp":1776679022,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，科美诊断报收于7.3元，较前一交易日上涨1.11%，最新总市值为29.28亿元。科美诊断技术股份有限公司于近日披露《关于自愿披露公司获得医疗器械注册证的公告》。公告显示，公司全资子公司科美博阳诊断技术（上海）有限公司近日获得上海市药品监督管理局颁发的《医疗器械注册证》，产品为磷酸化tau217蛋白检测试剂盒，注册类别为第二类，有效期至2031年4月10日，预期用途为供医疗机构用于体外定量检测人血浆中的p-tau217含量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000025729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1222","159883","BK1100","09996","BK1583","09997","688468"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628155710","title":"赛克赛斯上交所科创板IPO已问询 公司已拥有25款医疗器械产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2628155710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628155710?lang=zh_cn&edition=full","pubTime":"2026-04-20 15:45","pubTimestamp":1776671150,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月17日，赛克赛斯生物科技股份有限公司申请上交所科创板上市审核状态变更为“已问询”，光大证券为其保荐机构，拟募资6.35亿元。招股书显示，赛克赛斯专注于体内可吸收植介入医疗器械的研发、生产和销售。截至报告期末，公司已拥有25款医疗器械产品，其中多款产品为国内首创或独家产品，填补了相关领域技术空白。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1100","09997","BK1583","159982","IPOS","BK1222","159883","SPCX","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628316710","title":"艾柯医疗科创板IPO已问询 专注于神经介入创新医疗器械领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2628316710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628316710?lang=zh_cn&edition=full","pubTime":"2026-04-20 15:35","pubTimestamp":1776670547,"startTime":"0","endTime":"0","summary":"据招股书，公司是一家处于商业化阶段、专注于神经介入创新医疗器械领域的集研发、生产及商业化为一体的国家级高新技术企业，并荣获国家级专精特新“小巨人”认定。截至招股说明书签署日，公司已有包括创新医疗器械产品Lattice血流导向密网支架、Grism远端闭合颅内取栓支架、Attractor颅内血栓抽吸导管等在内的十款神经介入治疗及通路类第三类医疗器械于中国获批，并有产品陆续于美国、东南亚等海外市场获批或提交注册。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1100","BK1574","159883","159982","09997","BK1222","BK1583","IPOS","159891","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628760461","title":"5个工作日办结","url":"https://stock-news.laohu8.com/highlight/detail?id=2628760461","media":"海南特区报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628760461?lang=zh_cn&edition=full","pubTime":"2026-04-20 00:26","pubTimestamp":1776615960,"startTime":"0","endTime":"0","summary":"本报讯 近日，海口国家高新区医疗器械产业发展迎来新突破。驼人集团10项二类医疗器械注册证顺利完成由集团迁入，在此过程中，省药品监督管理局将原本需数周的审批流程压缩至5个工作日办结。　　据了解，驼人集团迁入的10项二类医疗器械注册证，涵盖了气管插管、导尿包、雾化器等一系列临床常用、受众广泛的一次性医用耗材。记者 钟起的\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-20/doc-inhvaisq4225797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09997","BK1222","BK1100","BK1583","BK1574","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628322733","title":"最高支持1000万元！“海珠脑机10条”来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2628322733","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628322733?lang=zh_cn&edition=full","pubTime":"2026-04-18 08:30","pubTimestamp":1776472200,"startTime":"0","endTime":"0","summary":"近日，海珠区推出“海珠脑机接口产业10条”政策，从研发创新到产品落地，从市场拓展到场景应用，全链条支持脑机接口产业发展。资质申报支持产品进入国家创新医疗器械特别审查或优先注册程序，最高支持20万元第三类医疗器械注册证：最高100万元第二类医疗器械注册证：最高30万元加速创新产品上市进程！海外市场拓展支持年度最高支持100万元助力企业出海抢单，打响国际品牌！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-18/doc-inhuwnkk5904597.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-18/doc-inhuwnkk5904597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","09997","BK1583","BK1574","BK1100","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627408264","title":"华创证券：平台型医疗器械公司稳健发展 建议关注国产IVD龙头拐点机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2627408264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627408264?lang=zh_cn&edition=full","pubTime":"2026-04-16 14:55","pubTimestamp":1776322516,"startTime":"0","endTime":"0","summary":"华创证券主要观点如下：总览海外器械龙头2025年呈现“平台稳、设备承压、耗材分化、IVD探底”的四分结构。从2025年各公司器械相关业务总营收来看，平台型公司2025年基本保持中高个位数或双位数同比，业绩增长稳健;设备类公司大多增速承压，仅手术机器人领域的直觉外科有20.5%的高增速;耗材类公司根据不同赛道有较大增速差异;IVD类公司普遍承压，仅生物梅里埃实现中个位数增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","161027","BK1222","09996","09997","BK1100","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627325669","title":"A股药企薪酬图鉴 创新药、CXO、高端医疗器械赛道人均薪酬领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2627325669","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627325669?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:00","pubTimestamp":1776294000,"startTime":"0","endTime":"0","summary":"随着A股年报相继出炉，各企业年薪再次成为焦点。截至2026年4月初，A股已有130家医药生物上市公司完整披露2025年人均薪酬数据。同花顺问财数据显示，医药行业内部薪酬分化极为显著，创新药、CXO、高端医疗器械三大赛道凭借高研发投入与技术壁垒，人均薪酬遥遥领先；而传统仿制药、中药、医药流通等领域则深陷薪酬洼地，行业最高与最低企业年薪差距超8倍。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","BK1100","BK1574","159883","159982","BK1161","399300","09997","BK1222","BK1583","CXO","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627029464","title":"迈普医学(301033.SZ)：硬脊膜医用胶产品进入创新医疗器械特别审查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2627029464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627029464?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:45","pubTimestamp":1776242701,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈普医学(301033.SZ)公告，公司自主研发的硬脊膜医用胶产品于近日获国家药品监督管理局医疗器械技术审评中心同意，进入创新医疗器械特别审查程序。硬脊膜医用胶适用于硬脊膜缝合部位的辅助封合，防止脑脊液渗漏。本产品以亲电亲核反应为基础，通过全球领先的专利技术配方以及辅助配件，在术中高效完成硬脊膜缝合部位的即时封堵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","159883","09997","09996","301033","BK1583","BK0251","BK1574","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627402650","title":"迈瑞医疗：希望用未来十年时间进入全球前10名医疗器械公司的榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2627402650","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627402650?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:36","pubTimestamp":1776242168,"startTime":"0","endTime":"0","summary":"证券之星消息，迈瑞医疗04月15日在投资者关系平台上答复投资者关心的问题。公司目前正在申请港股上市，本次港股上市，我们尤其关注国际市场，这将是迈瑞未来大有所为的舞台。未来五年，我们不可避免将与成熟的全球头部医疗器械企业在国际市场上正面竞争，我们要逐渐向他们看齐，这个底气来自于迈瑞深耕行业几十年所掌握的核心技术，甚至在很多方面，我们已经达到行业领先水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500029558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","LU1064131003.USD","BK1574","IE0008368742.USD","LU0405327148.USD","LU1781817850.SGD","LU1934453819.USD","LU0605514214.HKD","LU1655091616.SGD","LU1734074674.USD","LU0594300419.USD","LU2148510915.USD","LU2153591404.USD","LU0359202008.SGD","SGXZ81163826.USD","LU0327786744.USD","LU1720050803.USD","LU1979443071.USD","159883","BK1583","LU2213484517.USD","LU1997245094.SGD","LU0823426480.USD","SGXZ49509284.SGD","LU1146622755.USD","LU1820825898.SGD","BK0251","IE00B031J352.USD","BK1222","LU1580142542.USD","LU2424517915.HKD","IE00B031HY20.USD","300760","LU1023057109.AUD","LU0405327494.USD","LU1688375341.USD","LU0594300179.USD","LU1794554557.SGD","LU2153592121.USD","LU1997245177.USD","LU2488822045.USD","BK1100","IE0031814852.USD","LU0084288322.USD","LU0572944931.SGD","LU0359201612.USD","09996","LU0823426308.USD","LU0650527681.SGD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627461284","title":"谁在“裸泳”，谁有“余粮”？医械行业2025业绩加速分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2627461284","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627461284?lang=zh_cn&edition=full","pubTime":"2026-04-14 07:00","pubTimestamp":1776121200,"startTime":"0","endTime":"0","summary":"2025年，“十四五”收官之年，也是集采政策全面落地、医保支付改革走向深水区的关键节点。这一年，A股医疗器械行业在挑战与机遇的夹缝中，交出了一份“冰火两重天”的成绩单：有龙头企业上市后首次遭遇营收净利“双降”，也有高端装备企业逆势实现近50%的净利增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143703511010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143703511010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09996","BK1100","09997","BK1222","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627643372","title":"AI赋能千行百业一线观察｜当AI让医疗器械“长出大脑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627643372","media":"新华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627643372?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:20","pubTimestamp":1776068455,"startTime":"0","endTime":"0","summary":"新华网上海4月13日电清晨，上海国家会展中心刚开馆，人流迅速涌入主通道。设备提示音、屏幕刷新声与现场讲解交织在一起，仿佛置身真实“医疗现场”。一侧，大型影像设备完成扫描后，数秒内输出结构化分析结果；另一侧，手术机器人在模拟环境中完成精细路径操作；不远处，连续血糖曲线正在实时生成并给出趋势提示。在人群密集的一角，一套非侵入式脑机接口设备前，观众围起了圈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702881466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AIPO","ARTY","CHAT","09997","AGIX","09996","159883","BK1222","BK1583","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":-0.095},{"period":"1month","weight":0.0898},{"period":"3month","weight":-0.0621},{"period":"6month","weight":0.0317},{"period":"1year","weight":0.1657},{"period":"ytd","weight":0.03}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0399},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.1653},{"period":"ytd","weight":0.0057}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.057115},{"month":2,"riseRate":0.5,"avgChangeRate":0.017515},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100991},{"month":4,"riseRate":0.8,"avgChangeRate":0.053778},{"month":5,"riseRate":0.75,"avgChangeRate":-0.061692},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07739},{"month":7,"riseRate":0.5,"avgChangeRate":0.047595},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.086603},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.083675}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}